443 related articles for article (PubMed ID: 19797911)
1. Fibroblast growth factor 23 and matrix-metalloproteinases in patients with chronic kidney disease: are they associated with cardiovascular disease?
Peiskerová M; Kalousová M; Kratochvílová M; Dusilová-Sulková S; Uhrová J; Bandúr S; Malbohan IM; Zima T; Tesar V
Kidney Blood Press Res; 2009; 32(4):276-83. PubMed ID: 19797911
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.
Gutierrez O; Isakova T; Rhee E; Shah A; Holmes J; Collerone G; Jüppner H; Wolf M
J Am Soc Nephrol; 2005 Jul; 16(7):2205-15. PubMed ID: 15917335
[TBL] [Abstract][Full Text] [Related]
3. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients.
Jean G; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C
Nephrol Dial Transplant; 2009 Sep; 24(9):2792-6. PubMed ID: 19395730
[TBL] [Abstract][Full Text] [Related]
4. FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart.
Ford ML; Smith ER; Tomlinson LA; Chatterjee PK; Rajkumar C; Holt SG
Nephrol Dial Transplant; 2012 Feb; 27(2):727-33. PubMed ID: 21750158
[TBL] [Abstract][Full Text] [Related]
5. Determinants of circulating matrix metalloproteinase-2 and pregnancy-associated plasma protein-A in patients with chronic kidney disease.
Zakiyanov O; Kalousová M; Kratochvilová M; Kríha V; Zima T; Tesar V
Clin Lab; 2012; 58(5-6):471-80. PubMed ID: 22783577
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor 23 in chronic kidney disease: New insights and clinical implications.
Damasiewicz MJ; Toussaint ND; Polkinghorne KR
Nephrology (Carlton); 2011 Mar; 16(3):261-8. PubMed ID: 21265930
[TBL] [Abstract][Full Text] [Related]
7. Circulating matrix metalloproteinase-2 is an independent correlate of proteinuria in patients with chronic kidney disease.
Nagano M; Fukami K; Yamagishi S; Ueda S; Kaida Y; Matsumoto T; Yoshimura J; Hazama T; Takamiya Y; Kusumoto T; Gohara S; Tanaka H; Adachi H; Okuda S
Am J Nephrol; 2009; 29(2):109-15. PubMed ID: 18701818
[TBL] [Abstract][Full Text] [Related]
8. Regulation of fibroblast growth factor-23 in chronic kidney disease.
Westerberg PA; Linde T; Wikström B; Ljunggren O; Stridsberg M; Larsson TE
Nephrol Dial Transplant; 2007 Nov; 22(11):3202-7. PubMed ID: 17567652
[TBL] [Abstract][Full Text] [Related]
9. Relationships between circulating matrix metalloproteinase-2 and -9 and renal function in patients with chronic kidney disease.
Chang HR; Yang SF; Li ML; Lin CC; Hsieh YS; Lian JD
Clin Chim Acta; 2006 Apr; 366(1-2):243-8. PubMed ID: 16313894
[TBL] [Abstract][Full Text] [Related]
10. FGF-23: the rise of a novel cardiovascular risk marker in CKD.
Heine GH; Seiler S; Fliser D
Nephrol Dial Transplant; 2012 Aug; 27(8):3072-81. PubMed ID: 22851630
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of human fibroblast growth factor 23 (FGF-23) C-terminal and intact enzyme-linked immunosorbent-assays in end-stage renal disease patients.
Fassbender WJ; Brandenburg V; Schmitz S; Sandig D; Simon SA; Windolf J; Stumpf UC
Clin Lab; 2009; 55(3-4):144-52. PubMed ID: 19462937
[TBL] [Abstract][Full Text] [Related]
12. Mineral metabolism disturbances in patients with chronic kidney disease.
Kestenbaum B; Belozeroff V
Eur J Clin Invest; 2007 Aug; 37(8):607-22. PubMed ID: 17635571
[TBL] [Abstract][Full Text] [Related]
13. Emerging role of a phosphatonin in mineral homeostasis and its derangements.
Bielesz B
Eur J Clin Invest; 2006 Aug; 36 Suppl 2():34-42. PubMed ID: 16884396
[TBL] [Abstract][Full Text] [Related]
14. The impact of diabetes mellitus on vitamin D metabolism in predialysis patients.
Tanaka H; Hamano T; Fujii N; Tomida K; Matsui I; Mikami S; Nagasawa Y; Ito T; Moriyama T; Horio M; Imai E; Isaka Y; Rakugi H
Bone; 2009 Nov; 45(5):949-55. PubMed ID: 19631779
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase-2 and -9 exacerbate arterial stiffening and angiogenesis in diabetes and chronic kidney disease.
Chung AW; Yang HH; Sigrist MK; Brin G; Chum E; Gourlay WA; Levin A
Cardiovasc Res; 2009 Dec; 84(3):494-504. PubMed ID: 19617223
[TBL] [Abstract][Full Text] [Related]
16. Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP).
Bhuriya R; Li S; Chen SC; McCullough PA; Bakris GL
Am J Kidney Dis; 2009 Apr; 53(4 Suppl 4):S3-10. PubMed ID: 19285609
[TBL] [Abstract][Full Text] [Related]
17. Serum fibroblast growth factor-21 concentration is associated with residual renal function and insulin resistance in end-stage renal disease patients receiving long-term peritoneal dialysis.
Han SH; Choi SH; Cho BJ; Lee Y; Lim S; Park YJ; Moon MK; Lee HK; Kang SW; Han DS; Kim YB; Jang HC; Park KS
Metabolism; 2010 Nov; 59(11):1656-62. PubMed ID: 20423749
[TBL] [Abstract][Full Text] [Related]
18. Regulatory mechanisms of circulating fibroblast growth factor 23 in parathyroid diseases.
Imanishi Y; Kobayashi K; Kawata T; Inaba M; Nishizawa Y
Ther Apher Dial; 2007 Oct; 11 Suppl 1():S32-7. PubMed ID: 17976083
[TBL] [Abstract][Full Text] [Related]
19. Association of activated vitamin D treatment and mortality in chronic kidney disease.
Kovesdy CP; Ahmadzadeh S; Anderson JE; Kalantar-Zadeh K
Arch Intern Med; 2008 Feb; 168(4):397-403. PubMed ID: 18299495
[TBL] [Abstract][Full Text] [Related]
20. Effect of hemodiafiltration on pregnancy-associated plasma protein A (PAPP-A) and related parameters.
Kalousová M; Hodková M; Dusilová-Sulková S; Uhrová J; Tesar V; Zima T
Ren Fail; 2006; 28(8):715-21. PubMed ID: 17162432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
